USPTO Grants Key Mechanism of Action Patent to Bonum Therapeutics for its Conditionally Active Biologics Technology
Saved in:
| Title: | USPTO Grants Key Mechanism of Action Patent to Bonum Therapeutics for its Conditionally Active Biologics Technology |
|---|---|
| Authors: | Bonum Therapeutics |
| Source: | Business Wire (English). 08/13/2025. |
| Abstract: | Bonum Therapeutics, a biotechnology company developing conditionally regulated, highly active, less toxic medicines, today announced that the U.S. Patent and Trademark Office has granted it a key patent covering its dual-binding antibody (DBA) technology. The patent protects Bonum’s mechanism for regulating cytokine activity of marker-specific binding pairs, including LRRC15-IFNa, PD-L1-IFNa, PD1-IL2, and others. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Bonum Therapeutics, a biotechnology company developing conditionally regulated, highly active, less toxic medicines, today announced that the U.S. Patent and Trademark Office has granted it a key patent covering its dual-binding antibody (DBA) technology. The patent protects Bonum’s mechanism for regulating cytokine activity of marker-specific binding pairs, including LRRC15-IFNa, PD-L1-IFNa, PD1-IL2, and others. [ABSTRACT FROM PUBLISHER] |
|---|
